Premium
Study of antiapoptotic gene of oral carcinoma by using Bcl‐2 oncogene
Author(s) -
Kummoona Raja,
Mohammad Sámi Suha,
AlKapptan Ikpal,
AlMuala Header
Publication year - 2008
Publication title -
journal of oral pathology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.887
H-Index - 83
eISSN - 1600-0714
pISSN - 0904-2512
DOI - 10.1111/j.1600-0714.2007.00624.x
Subject(s) - oncogene , carcinoma , pathology , immunohistochemistry , histopathology , medicine , radiation therapy , metastasis , molecular medicine , basal cell , cancer , biology , cancer research , cell cycle
The present study was addressed to find out the expression of Bcl‐2 proto‐oncogene in tumor tissue derived from 24 patients with malignant oral carcinoma and oral mucosa from the same patients served as control and showed a cytoplasmic pattern of Bcl‐2 immunoreactivity in basal cell layer. Fourteen of 24 (58.3%) of oral carcinoma and four adenocystic carcinoma expressed positive Bcl‐2 oncogene. Well‐differentiated squamous cell carcinoma showed absence of immunoreactivity. No statistically significant correlation could be demonstrated between Bcl‐2 immunoreactivity and the age or sex of the patients, tumor size, and lymph node metastasis. A direct correlation between Bcl‐2 immunoreactivity in G2 and G3 was statistically significant ( P < 0.05). Patients with absence of or low (scores 0 or 1) Bcl‐2 immunoreactive tumors manifested poorer overall survival rate in comparison with patients with moderate or high (scores 2 and 3) Bcl‐2 expression, but the difference was not statistically significant. Tumors exhibited three different expressions of Bcl‐2 (weak, moderate, and strong positive), compared to the mucosa of some patients affected by these tumors. No correlation was found between the histopathology of the tumors, mucosal expression, and degree of Bcl‐2 expression. We propose from this study that overexpression of Bcl‐2 proto‐oncogene acts as a strong antiapoptotic in both squamous cells and adenocystic carcinoma may be an important molecular event on oral carcinoma to make these tumors resistant to radiotherapy and chemotherapy.